Solana (HSDT) Competitors

$2.30 -0.06 (-2.50%)

As of 01:49 PM Eastern

HSDT vs. KIDS, BBNX, DCTH, CLPT, and CV

Should you buy Solana stock or one of its competitors? MarketBeat compares Solana with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Solana include OrthoPediatrics (KIDS), Beta Bionics (BBNX), Delcath Systems (DCTH), ClearPoint Neuro (CLPT), and CapsoVision (CV). These companies are all part of the "medical equipment" industry.

How does Solana compare to OrthoPediatrics?

OrthoPediatrics (NASDAQ:KIDS) and Solana (NASDAQ:HSDT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

OrthoPediatrics currently has a consensus target price of $24.44, indicating a potential upside of 32.85%. Solana has a consensus target price of $3.50, indicating a potential upside of 52.11%. Given Solana's higher possible upside, analysts plainly believe Solana is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

OrthoPediatrics has a net margin of -16.31% compared to Solana's net margin of -1,427.15%. OrthoPediatrics' return on equity of -7.01% beat Solana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-16.31%	-7.01%	-4.86%
Solana	-1,427.15%	-67.57%	-24.09%

In the previous week, Solana had 5 more articles in the media than OrthoPediatrics. MarketBeat recorded 6 mentions for Solana and 1 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 1.57 beat Solana's score of -0.34 indicating that OrthoPediatrics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OrthoPediatrics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Solana	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

OrthoPediatrics has higher revenue and earnings than Solana. OrthoPediatrics is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$236.35M	2.00	-$39.65M	-$1.68	N/A
Solana	$6.02M	22.32	-$40.89M	-$109.67	N/A

69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 18.6% of Solana shares are held by institutional investors. 32.7% of OrthoPediatrics shares are held by insiders. Comparatively, 14.4% of Solana shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

OrthoPediatrics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Solana has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Summary

OrthoPediatrics beats Solana on 11 of the 16 factors compared between the two stocks.

How does Solana compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Solana (NASDAQ:HSDT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

18.6% of Solana shares are held by institutional investors. 5.3% of Beta Bionics shares are held by insiders. Comparatively, 14.4% of Solana shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Solana has lower revenue, but higher earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	5.25	-$73.20M	-$1.51	N/A
Solana	$6.02M	22.32	-$40.89M	-$109.67	N/A

Beta Bionics has a net margin of -60.27% compared to Solana's net margin of -1,427.15%. Beta Bionics' return on equity of -23.00% beat Solana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Solana	-1,427.15%	-67.57%	-24.09%

In the previous week, Solana had 2 more articles in the media than Beta Bionics. MarketBeat recorded 6 mentions for Solana and 4 mentions for Beta Bionics. Beta Bionics' average media sentiment score of -0.34 beat Solana's score of -0.34 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solana	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Beta Bionics presently has a consensus price target of $20.00, suggesting a potential upside of 69.42%. Solana has a consensus price target of $3.50, suggesting a potential upside of 52.11%. Given Beta Bionics' stronger consensus rating and higher possible upside, research analysts plainly believe Beta Bionics is more favorable than Solana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Beta Bionics has a beta of 3.29, meaning that its stock price is 229% more volatile than the broader market. Comparatively, Solana has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Summary

Beta Bionics beats Solana on 10 of the 16 factors compared between the two stocks.

How does Solana compare to Delcath Systems?

Solana (NASDAQ:HSDT) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Solana has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

18.6% of Solana shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 14.4% of Solana shares are held by company insiders. Comparatively, 19.4% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Solana presently has a consensus target price of $3.50, suggesting a potential upside of 52.11%. Delcath Systems has a consensus target price of $22.50, suggesting a potential upside of 100.09%. Given Delcath Systems' higher possible upside, analysts clearly believe Delcath Systems is more favorable than Solana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Solana had 3 more articles in the media than Delcath Systems. MarketBeat recorded 6 mentions for Solana and 3 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 0.00 beat Solana's score of -0.34 indicating that Delcath Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solana	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Delcath Systems	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Delcath Systems has a net margin of 0.62% compared to Solana's net margin of -1,427.15%. Delcath Systems' return on equity of 0.51% beat Solana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solana	-1,427.15%	-67.57%	-24.09%
Delcath Systems	0.62%	0.51%	0.46%

Delcath Systems has higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$6.02M	22.32	-$40.89M	-$109.67	N/A
Delcath Systems	$85.23M	4.55	$2.70M	$0.01	1,124.50

Summary

Delcath Systems beats Solana on 12 of the 17 factors compared between the two stocks.

How does Solana compare to ClearPoint Neuro?

Solana (NASDAQ:HSDT) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Solana currently has a consensus price target of $3.50, suggesting a potential upside of 52.11%. ClearPoint Neuro has a consensus price target of $18.00, suggesting a potential upside of 55.78%. Given ClearPoint Neuro's higher probable upside, analysts plainly believe ClearPoint Neuro is more favorable than Solana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

ClearPoint Neuro has higher revenue and earnings than Solana. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$6.02M	22.32	-$40.89M	-$109.67	N/A
ClearPoint Neuro	$36.97M	9.37	-$25.54M	-$1.01	N/A

Solana has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

In the previous week, Solana had 1 more articles in the media than ClearPoint Neuro. MarketBeat recorded 6 mentions for Solana and 5 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of -0.02 beat Solana's score of -0.34 indicating that ClearPoint Neuro is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solana	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ClearPoint Neuro	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ClearPoint Neuro has a net margin of -71.57% compared to Solana's net margin of -1,427.15%. Solana's return on equity of -67.57% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solana	-1,427.15%	-67.57%	-24.09%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

18.6% of Solana shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 14.4% of Solana shares are held by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

ClearPoint Neuro beats Solana on 9 of the 17 factors compared between the two stocks.

How does Solana compare to CapsoVision?

Solana (NASDAQ:HSDT) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

18.6% of Solana shares are owned by institutional investors. 14.4% of Solana shares are owned by company insiders. Comparatively, 2.3% of CapsoVision shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Solana had 5 more articles in the media than CapsoVision. MarketBeat recorded 6 mentions for Solana and 1 mentions for CapsoVision. CapsoVision's average media sentiment score of 0.00 beat Solana's score of -0.34 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solana	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solana currently has a consensus target price of $3.50, indicating a potential upside of 52.11%. CapsoVision has a consensus target price of $8.50, indicating a potential upside of 26.47%. Given Solana's higher probable upside, research analysts clearly believe Solana is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

CapsoVision has higher revenue and earnings than Solana. CapsoVision is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$6.02M	22.32	-$40.89M	-$109.67	N/A
CapsoVision	$13.55M	24.78	-$25.32M	-$2.34	N/A

CapsoVision has a net margin of -198.87% compared to Solana's net margin of -1,427.15%. CapsoVision's return on equity of 0.00% beat Solana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solana	-1,427.15%	-67.57%	-24.09%
CapsoVision	-198.87%	N/A	-136.03%

Summary

CapsoVision beats Solana on 7 of the 13 factors compared between the two stocks.

Get Solana News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSDT vs. The Competition

Export

Metric	Solana	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$134.59M	$6.97B	$6.38B	$12.34B
Dividend Yield	N/A	1.67%	2.79%	5.33%
P/E Ratio	-0.02	49.72	20.91	25.65
Price / Sales	22.32	84.92	543.80	85.61
Price / Cash	N/A	25.00	44.13	56.16
Price / Book	0.68	6.47	10.09	7.06
Net Income	-$40.89M	$158.81M	$3.55B	$335.04M
7 Day Performance	0.04%	3.55%	4.71%	2.60%
1 Month Performance	10.10%	-1.84%	1.43%	1.42%
1 Year Performance	-98.96%	2.24%	36.72%	35.67%

Solana Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HSDT Solana	3.5265 of 5 stars	$2.30 -2.5%	$3.50 +52.1%	-98.9%	$134.59M	$6.02M	N/A	30	Earnings Report
KIDS OrthoPediatrics	3.7395 of 5 stars	$17.72 +3.1%	$24.44 +37.9%	-15.7%	$455.05M	$236.35M	N/A	200	Positive News
BBNX Beta Bionics	3.1908 of 5 stars	$9.82 -0.3%	$22.00 +124.0%	-31.8%	$437.58M	$100.25M	N/A	294	Positive News
DCTH Delcath Systems	1.7864 of 5 stars	$11.34 +2.5%	$22.50 +98.4%	-33.6%	$391.46M	$85.23M	1,134.00	60
CLPT ClearPoint Neuro	2.0106 of 5 stars	$12.64 +2.7%	$18.00 +42.4%	-3.8%	$379.02M	$36.97M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HSDT) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solana (HSDT) Competitors

HSDT vs. KIDS, BBNX, DCTH, CLPT, and CV

How does Solana compare to OrthoPediatrics?

Summary

How does Solana compare to Beta Bionics?

Summary

How does Solana compare to Delcath Systems?

Summary

How does Solana compare to ClearPoint Neuro?

Summary

How does Solana compare to CapsoVision?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSDT vs. The Competition

Solana Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solana (HSDT) Competitors

HSDT vs. KIDS, BBNX, DCTH, CLPT, and CV

How does Solana compare to OrthoPediatrics?

Do analysts prefer KIDS or HSDT?

Is KIDS or HSDT more profitable?

Does the media refer more to KIDS or HSDT?

Which has higher earnings & valuation, KIDS or HSDT?

Do insiders and institutionals believe in KIDS or HSDT?

Which has more volatility and risk, KIDS or HSDT?

Summary

How does Solana compare to Beta Bionics?

Do institutionals & insiders hold more shares of BBNX or HSDT?

Which has stronger valuation & earnings, BBNX or HSDT?

Is BBNX or HSDT more profitable?

Does the media refer more to BBNX or HSDT?

Do analysts recommend BBNX or HSDT?

Which has more risk and volatility, BBNX or HSDT?

Summary

How does Solana compare to Delcath Systems?

Which has more volatility and risk, HSDT or DCTH?

Do insiders and institutionals have more ownership in HSDT or DCTH?

Do analysts rate HSDT or DCTH?

Does the media favor HSDT or DCTH?

Is HSDT or DCTH more profitable?

Which has stronger earnings & valuation, HSDT or DCTH?

Summary

How does Solana compare to ClearPoint Neuro?

Do analysts rate HSDT or CLPT?

Which has better earnings and valuation, HSDT or CLPT?

Which has more risk & volatility, HSDT or CLPT?

Does the media favor HSDT or CLPT?

Is HSDT or CLPT more profitable?

Do insiders & institutionals have more ownership in HSDT or CLPT?

Summary

How does Solana compare to CapsoVision?

Do institutionals and insiders have more ownership in HSDT or CV?

Does the media favor HSDT or CV?

Do analysts rate HSDT or CV?

Which has preferable earnings & valuation, HSDT or CV?

Is HSDT or CV more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSDT vs. The Competition

Solana Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools